Learn if You Have a Claim Against McNeil-PPC, Inc. (maker of Motrin)

Consumers Horrified to Find Skin Blisters and Internal Burns from Using Motrin Kahn Gauthier Swick is investigating possible legal actions against Johnson and Johnson subsidiary McNeil-PPC, Inc., the maker of the popular over-the-counter painkiller Motrin, on behalf of Motrin users who have suffered a severe skin and mucus membrane reaction.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name
Age
Relationship
Motrin Use

Date you began taking Motrin
Date you stopped taking Motrin
Medical Information

Please describe the nature and extent of your injuries resulting from your use of Motrin. Particularly, did you suffer either Stevens-Johnson syndrome (SJS), or a very dangerous condition known as toxic epidermal necrolysis (TEN)?
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Pfizer Faces Antitrust Suit over Alleged Illegal Extension of Accupril Patent

There is irony in the way big American drugmakers’ pricing policies hurt the very people the companies are supposed to be helping. A class action has been filed against drugmaker Pfizer, Inc. on behalf of persons who paid out-of-pocket expenses for the hypertension treatment Accupril (quinapril hydrochloride tablets), who allege that the company has it legally maintained a monopoly on the drug by delaying generic competition, in violation of state and U.S. antitrust laws.

Aetna Heath Insureds in Pennsylvania Claim that Liens against Tort Recovery Are Invalid

A class action has been filed against Aetna Health, Inc., a subsidiary of healthcare giant Aetna, Inc., on behalf of Pennsylvania residents (1) who, between September 26, 1999, and the date of the final judgment in the action, were injured in a motor vehicle accident while insured under an Aetna heathcare plan; and (2) whose tort recovery from the accident was subject to a lien asserted by Aetna. The action seeks compensatory and statutory damages for monies collected via the liens as well as injunctive and declaratory relief.

Bayer Settles Canadian Baycol Claims for $9+ Million

The parties have reached a tentative nationwide $9+ million settlement in a class action filed against Bayer, Inc. on behalf of Canadians who live in any province other than British Columbia, and who were prescribed the anti-cholesterol drug Baycol (cerivastatin) and family members of deceased Canadians who took the drug. The action alleges that the drug causes the serious adverse muscle reaction known as rhabdomyolysis, and may also cause acute renal failure. The court has apparently not yet set a claims deadline-- persons eligible to take part in the settlement should contact attorneys for the class as soon as possible.

Medical Clinic Allegedly Withheld Care from Cancer Patients to Force them to Accept Settlement

A federal class action has been filed against the Kentucky based Trover Clinic Foundation and its associated network of hospitals and medical officers. The suit alleges that over 415 individuals who sued Trover Clinic in state court were subsequently contacted and told that they would not be treated at any Trover affiliated facility unless they accepted the terms of a settlement offer put forward by Trover. Many of the plaintiffs are cancer patients who would have been forced to seek treatment out of state as a result of Trover's refusal to treat them.

Intermune to Pay $37 Million for Promotion of Actimmune Drug

InterMune Inc., a biopharmaceutical company based out of California, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF).

Cambrex Announces That it Overstated its Net Income by $5 Million

A class action has been filed against chemical and pharmaceutical manufacturer Cambrex Corporation (NYSE: CBM) and certain of its officers and directors by stockholders who purchased the company's common stock between October 21, 1998, and July 25, 2003.